LimmaTech Biologics Raises USD 37m Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

12 October 2023

LimmaTech Biologics AG announced the closing of a USD 37m (CHF 33m) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhea. Later-stage clinical development efforts will focus on the company’s Shigella vaccine program, which LimmaTech developed as part of a joint collaboration with GSK and recently exclusively in-licensed. The company expects to announce preliminary results from the Shigella program’s ongoing Phase 2 clinical trial in the second half of 2023.

VISCHER acted as legal advisor to LimmaTech Biologics in the transaction. The VISCHER team includes Matthias Staehelin (Partner, Corporate/M&A), Nadia Tarolli (Partner, Tax), Pauline Pfirter (Senior Associate, Corporate/M&A) and Luzius Zumstein (Managing Associate, Corporate/M&A).